U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07951086) titled 'A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Rheumatoid Arthritis' on Nov. 16.
Brief Summary: The purpose of this Phase 2 study is:
1. to evaluate the efficacy, safety and tolerability of DDY391 in participants with moderate to severe active rheumatoid arthritis (RA).
2. to provide information about dose selection and study design for subsequent clinical development.
Study Start Date: Jan. 26, 2027
Study Type: INTERVENTIONAL
Condition:
Rheumatoid Arthritis
Intervention:
DRUG: DDY391
DDY391
DRUG: Placebo
Matching placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Novartis Ph...